Literature DB >> 3958780

Anguidine potentiates cis-platinum in human brain tumor cells.

R A Hromas, W K Yung.   

Abstract

Anguidine pretreatment was previously shown to potentiate cis-platinum in Chinese hamster ovary cells by 100-fold, probably by enhancing cellular cis-platinum uptake. Since both cis-platinum and anguidine have been reported to have clinical efficacy in human brain tumors, the present study was initiated to investigate whether anguidine's potentiation of cis-platinum was applicable to human brain tumor cells in culture. Using the colony formation assay, it was found that anguidine enhanced cis-platinum's cytotoxicity by ten-fold, producing a dose modification factor of 1.74. Alkaline elution analysis of cis-platinum-induced DNA cross-links found that anguidine enhanced cross-linking by a factor of 1.55, 1.76, 1.63, and 1.48 at 0, 6, 24, and 48 hr, respectively, after cis-platinum treatment. This enhancement of cross-linking is evidence for anguidine increasing cis-platinum uptake. Thus, anguidine enhances cis-platinum-induced DNA cross-linking and subsequent cytotoxicity in human brain tumor cells, and may be clinically useful in combination with cis-platinum in those tumors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3958780     DOI: 10.1007/bf00165584

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  22 in total

1.  Fractionation of DNA from mammalian cells by alkaline elution.

Authors:  K W Kohn; L C Erickson; R A Ewig; C A Friedman
Journal:  Biochemistry       Date:  1976-10-19       Impact factor: 3.162

2.  Chemotherapy of brain tumors.

Authors:  N A Vick; J D Khandekar; D D Bigner
Journal:  Arch Neurol       Date:  1977-09

3.  Radiotherapy and CCNU in the treatment of high-grade supratentorial astrocytomas.

Authors:  B Weir; P Band; R Urtasun; G Blain; D Mclean; F Wilson; B Mielke; M Grace
Journal:  J Neurosurg       Date:  1976-08       Impact factor: 5.115

4.  Phase I clinical evaluation of anguidine.

Authors:  W K Murphy; M A Burgess; M Valdivieso; R B Livingston; G P Bodey; E J Freireich
Journal:  Cancer Treat Rep       Date:  1978-10

5.  The treatment of glioblastoma multiforme of the brain.

Authors:  R Jelsma; P C Bucy
Journal:  J Neurosurg       Date:  1967-11       Impact factor: 5.115

6.  Phase II evaluation of anguidine in central nervous system tumors: a southwest Oncology Group study.

Authors:  J W Goodwin; R H Bottomley; C B Vaughn; J Frank; R P Pugh
Journal:  Cancer Treat Rep       Date:  1983-03

7.  Differential cytotoxicity and DNA cross-linking in normal and transformed human fibroblasts treated with cis-diamminedichloroplatinum(II).

Authors:  L C Erickson; L A Zwelling; J M Ducore; N A Sharkey; K W Kohn
Journal:  Cancer Res       Date:  1981-07       Impact factor: 12.701

8.  Comparative studies of DNA cross-linking and cytotoxicity in Burkitt's lymphoma cell lines treated with cis-diamminedichloroplatinum(II) and L-phenylalanine mustard.

Authors:  J M Ducore; L C Erickson; L A Zwelling; G Laurent; K W Kohn
Journal:  Cancer Res       Date:  1982-03       Impact factor: 12.701

9.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

10.  Potentiation of DNA-reactive antineoplastic agents and protection against S-phase-specific agents by anguidine in Chinese hamster ovary cells.

Authors:  R Hromas; B Barlogie; D Swartzendruber; B Drewinko
Journal:  Cancer Res       Date:  1983-07       Impact factor: 12.701

View more
  3 in total

Review 1.  Drug resistance in brain tumors.

Authors:  L G Feun; N Savaraj; H J Landy
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

2.  Preclinical antitumor activity of ethyldeshydroxysparsomycin in combination with cisplatin.

Authors:  H P Hofs; D J Wagener; V De Valk-Bakker; H Van Rennes; D De Vos; W H Doesburg; H C Ottenheijm; W J De Grip
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

3.  Diacetoxyscirpenol as a new anticancer agent to target hypoxia-inducible factor 1.

Authors:  Yong-Joon Choi; Hyun-Woo Shin; Yang-Sook Chun; Alain Simplice Leutou; Byeng Wha Son; Jong-Wan Park
Journal:  Oncotarget       Date:  2016-09-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.